As a veteran of the FDA Oncologic Drugs Advisory Committee, Maha Hussain took part in the group’s past discussions on treatment options for men with non-metastatic castration-resistant prostate cancer.
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.
